Illustrative pack image. Actual packaging may differ.
GLIMEFON-PM1 Tablet
Triple Drug Combination for Comprehensive Glycemic Control
Composition
Glimepiride 1 mg + Metformin Hydrochloride 500 mg SR + Pioglitazone 15 mg
- Prescription medicine
- Available to order
Overview
GLIMEFON-PM1 combines the synergistic actions of Glimepiride (a sulfonylurea), Metformin (a biguanide), and Pioglitazone (a thiazolidinedione) to provide a powerful triple therapy for the management of type 2 diabetes mellitus. This combination targets multiple pathophysiological defects of diabetes, offering superior glucose control and improved insulin sensitivity.
Key Benefits
- Triple mechanism: stimulates insulin secretion, reduces hepatic glucose output, and enhances peripheral insulin action
- Effective in managing insulin resistance and β-cell dysfunction
- Helps lower both fasting and postprandial blood glucose levels
- Reduces HbA1c significantly in poorly controlled diabetic patients
- Improves lipid profile and reduces cardiovascular risk factors
- Convenient once-daily dosing improves adherence
Indications
- Type 2 Diabetes Mellitus (especially in patients uncontrolled on dual therapy)
- Ideal for patients with high insulin resistance and inadequate glycemic control
- Prevents or delays diabetes-related complications
